NEW YORK (GenomeWeb) – LexaGene announced today that it has partnered with Texas A&M Veterinary Medical Diagnostics Laboratory to test canine urine samples on LexaGene's LX6 prototype pathogen detection instrument.
Veterinarians at Texas A&M will send LexaGene clinically annotated urine samples for processing and pathogen detection on the firm's LX6 device. Before sending the samples to LexaGene, Texas A&M will characterize them using current diagnostic technology.
LexaGene is developing its LX6 diagnostic tool as a fully automated platform that allows users to load multiple real-time PCR assays. The test will read six samples at a time and produce results in about an hour, the firm noted.
According to LexaGene CEO Jack Regan, the firm's assay will ultimately search for pathogens that thrive in different climates, including Rocky Mountain spotted fever, Borrelia burgdorferi, and Anaplasma phagocytophilum.
"It is important for us to work with collaborators in different geographic regions ... as this allows us to continue to refine our assays and optimize the LX6 prototype," Regan said in a statement.
Financial terms of the deal were not disclosed.
In April, LexaGene partnered with Ethos Veterinary Health to test canine urine samples on the firm's LX6 prototype pathogen detection instrument.